Alitair Announces Patent Allowance for Platform Delivery Technology
Alitair Pharmaceuticals, Inc., a mid-stage pharmaceutical company with multiple respiratory product candidates in development, recently announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ion-exchange resin platform drug delivery technology, REA. Alitair has out-licensed two product candidates utilizing its REA platform technology, and additional product candidates are available for out-licensing.
“Our propriety ion exchange resin delivery platform can be utilized across a range of therapeutic classes and with many different molecules,” said Alitair President and CEO, William W. Howard, PhD. “The REA platform technology allows us to improve upon currently available therapies and create new oral-solid formulations with less-frequent dosing schedules, both of which have been shown to improve patient adherence.”
“Receiving this Notice of Allowance is an important milestone in our product development strategy and the growth of Alitair,” continued Mr. Howard. “We will continue to pursue additional patent protection in the
Alitair Pharmaceuticals, Inc. discovers, invents, and develops medicines for the treatment of respiratory illnesses. Alitair has out-licensed two prescription cough candidates that use its proprietary ion-exchange resin technology, REA, and other product candidates are available for out-licensing. Additional information about Alitair is available at www.alitair.com or by calling Faith Pomeroy-Ward, Vice President, Corporate Development, at 817-490-5152 or emailing at faith@alitair.com.
Total Page Views: 1027
